Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 6/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751587 | 0.86 | P2RX7 (0.39) | FSCN1P2RX7 | |
| SCHEMBL4750000 | 0.84 | FSCN1 (0.43) | CHRM1FSCN1TOP1PDPK1 | |
| SCHEMBL4743539 | 0.83 | FSCN1 (0.43) | CHRM1FSCN1P2RX7PDPK1 | |
| SCHEMBL4745171 | 0.83 | P2RX3 (0.40) | FSCN1P2RX7 | |
| SCHEMBL4749999 | 0.83 | P2RX7 (0.39) | FSCN1P2RX7 | |
| SCHEMBL4748066 | 0.82 | P2RX7 (0.37) | FSCN1P2RX7 | |
| SCHEMBL4745146 | 0.82 | P2RX7 (0.35) | FSCN1P2RX7 | |
| SCHEMBL4746117 | 0.81 | FSCN1 (0.42) | CHRM1FSCN1P2RX7 | |
| SCHEMBL4746320 | 0.81 | FSCN1 (0.40) | CHRM1FSCN1P2RX7PDPK1 | |
| SCHEMBL4744320 | 0.81 | P2RX7 (0.36) | FSCN1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | DHPS, DPYD, TYMP | CHRM1 1224/4885FSCN1 4879/4885TOP1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.